Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.
- Citation:
- Pharmacogenomics J vol 24 (4) 22
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233341, UG1CA233373
- Corr. Author:
- Authors:
- Julia C F Quintanilha William Kevin Kelly Federico Innocenti
- Networks:
- LAPS-NC007
- Study
- Alliance-A152114
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-90401
- Phases:
- N/A, 3
- Keywords: